Cargando…

Expression of microRNA-181 determines response to treatment with azacitidine and predicts survival in elderly patients with acute myeloid leukaemia

MicroRNAs (miRs) are small non-coding RNAs that play important roles in cell differentiation and survival. Abnormal expression of miRs has been demonstrated in numerous types of cancer, including acute myeloid leukaemia (AML). The aim of the present study was to evaluate miR-181 expression at diagno...

Descripción completa

Detalles Bibliográficos
Autores principales:	Butrym, Aleksandra, Rybka, Justyna, Baczyńska, Dagmara, Poręba, Rafał, Mazur, Grzegorz, Kuliczkowski, Kazimierz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2016
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5038519/ https://www.ncbi.nlm.nih.gov/pubmed/27698792 http://dx.doi.org/10.3892/ol.2016.4970

Ejemplares similares

Clinical response to azacitidine therapy depends on microRNA-29c (miR-29c) expression in older acute myeloid leukemia (AML) patients
por: Butrym, Aleksandra, et al.
Publicado: (2016)

Low expression of microRNA-204 (miR-204) is associated with poor clinical outcome of acute myeloid leukemia (AML) patients
por: Butrym, Aleksandra, et al.
Publicado: (2015)

Azacitidine in outpatient treatment – single center experience
por: Rybka, Justyna, et al.
Publicado: (2016)

Genetic variation of the gene coding for microRNA-204 (miR-204) is a risk factor in acute myeloid leukaemia
por: Butrym, Aleksandra, et al.
Publicado: (2018)

The expression of Toll-like receptors and development of severe sepsis in patients with acute myeloid leukemias after induction chemotherapy
por: Rybka, Justyna, et al.
Publicado: (2014)

The Expression of Toll-Like Receptors in Patients with B-Cell Chronic Lymphocytic Leukemia
por: Rybka, Justyna, et al.
Publicado: (2017)

High CD74 expression correlates with ZAP70 expression in B cell chronic lymphocytic leukemia patients
por: Butrym, Aleksandra, et al.
Publicado: (2013)

TERT genetic variability and telomere length as factors affecting survival and risk in acute myeloid leukaemia
por: Dratwa, Marta, et al.
Publicado: (2021)

BSG (CD147) Serum Level and Genetic Variants Are Associated with Overall Survival in Acute Myeloid Leukaemia
por: Łacina, Piotr, et al.
Publicado: (2022)

Endothelial Function in Patients with Hematologic Malignancies Undergoing High-Dose Chemotherapy Followed by Hematopoietic Stem Cell Transplantation
por: Poręba, Małgorzata, et al.
Publicado: (2015)

Decreased Expression of CXCR4 Chemokine Receptor in Bone Marrow after Chemotherapy in Patients with Non-Hodgkin Lymphomas Is a Good Prognostic Factor
por: Mazur, Grzegorz, et al.
Publicado: (2014)

Evaluation of the impact of treatment with hematopoietic stem cells transplantation (HSCT) on biochemical markers of heart function and novel electrocardiographic markers of repolarization in patients with hematological malignancies
por: Poręba, Małgorzata, et al.
Publicado: (2018)

Cereblon and IRF4 Variants Affect Risk and Response to Treatment in Multiple Myeloma
por: Butrym, Aleksandra, et al.
Publicado: (2017)

Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens
por: Seymour, John F., et al.
Publicado: (2017)

FUS-ERG induces late-onset azacitidine resistance in acute myeloid leukaemia cells
por: Asai-Nishishita, Ai, et al.
Publicado: (2023)

IL-17F gene polymorphism is associated with susceptibility to acute myeloid leukemia
por: Wróbel, Tomasz, et al.
Publicado: (2014)

MicroRNAs: new players in acute myeloid leukaemia
por: Havelange, V, et al.
Publicado: (2009)

VEGF and bFGF gene polymorphisms in Polish patients with B-CLL
por: Wróbel, Tomasz, et al.
Publicado: (2013)

VEGF and bFGF Gene Polymorphisms in Patients with Non-Hodgkin's Lymphoma
por: Wróbel, Tomasz, et al.
Publicado: (2013)

Use of Azacitidine or Decitabine for the Up-Front Setting in Acute Myeloid Leukaemia: A Systematic Review and Meta-Analysis
por: Saiz-Rodríguez, Miriam, et al.
Publicado: (2021)

Epigenetic therapy with chidamide alone or combined with 5-azacitidine exerts antitumour effects on acute myeloid leukaemia cells in vitro
por: Li, Zheng, et al.
Publicado: (2022)

Iron Dysregulation and Frailty Syndrome
por: Zawadzki, Bartosz, et al.
Publicado: (2021)

Asymmetric and symmetric dimethylarginines and mortality in patients with hematological malignancies—A prospective study
por: Chachaj, Angelika, et al.
Publicado: (2018)

Efficacy and tolerability of treatment with azacitidine for 5 days in elderly patients with acute myeloid leukemia
por: Sadashiv, Santhosh K, et al.
Publicado: (2014)

Economic Evaluation of Azacitidine in Elderly Patients with Acute Myeloid Leukemia with High Blast Counts
por: Coyle, D., et al.
Publicado: (2019)

Successful Treatment of Myeloid Sarcoma in an Elderly Patient with Myelodysplastic Syndrome with Reduced-Dose Azacitidine
por: Sato, Kazuya, et al.
Publicado: (2021)

Benefit of the Reduced Dose Combination of Azacitidine and Venetoclax in an Elderly Patient With Acute Myeloid Leukemia
por: Fujino, Keita, et al.
Publicado: (2023)

Serum NMR metabolomics to differentiate haematologic malignancies
por: Wojtowicz, Wojciech, et al.
Publicado: (2018)

MicroRNA-181a enhances the chemotherapeutic sensitivity of chronic myeloid leukemia to imatinib
por: WANG, GUANGYU, et al.
Publicado: (2015)

MicroRNA control of myelopoiesis and the differentiation block in acute myeloid leukaemia
por: Palma, Catalina A, et al.
Publicado: (2012)

Diagnostic & prognostic role of microRNAs in paediatric acute myeloid leukaemia
por: Kumar, Sachin, et al.
Publicado: (2016)

microRNA expression in acute myeloid leukaemia: New targets for therapy?
por: Fletcher, Daniel, et al.
Publicado: (2022)

Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)
por: Butrym, Aleksandra, et al.
Publicado: (2015)

Distinctive Patterns of MicroRNA Expression Associated with Karyotype in Acute Myeloid Leukaemia
por: Dixon-McIver, Amanda, et al.
Publicado: (2008)

MicroRNA-155 as an inducer of apoptosis and cell differentiation in Acute Myeloid Leukaemia
por: Palma, Catalina A, et al.
Publicado: (2014)

Outcome of therapy-related myeloid neoplasms treated with azacitidine
por: Fianchi, Luana, et al.
Publicado: (2012)

Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an update
por: Fenaux, P, et al.
Publicado: (2008)

Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications
por: Pleyer, Lisa, et al.
Publicado: (2016)

A Combined Histone Deacetylases Targeting Strategy to Overcome Venetoclax Plus Azacitidine Regimen Resistance in Acute Myeloid Leukaemia: Three Case Reports
por: Wang, Bin-Ru, et al.
Publicado: (2021)

The Role of Azacitidine in the Treatment of Elderly Patients with Acute Myeloid Leukemia: Results of a Retrospective Multicenter Study
por: Tombak, Anıl, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_b91kqtasjjutcrns5hmmakobtg